Entera Bio Ltd.

NASDAQ:ENTX

1.8 (USD) • At close November 1, 2024
Bedrijfsnaam Entera Bio Ltd.
Symbool ENTX
Munteenheid USD
Prijs 1.8
Beurswaarde 65,384,280
Dividendpercentage 0%
52-weken bereik 0.52 - 3.35
Industrie Biotechnology
Sector Healthcare
CEO Ms. Miranda J. Toledano M.B.A.
Website https://www.enterabio.com

An error occurred while fetching data.

Over Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II

Vergelijkbare Aandelen

Seelos Therapeutics, Inc. logo

Seelos Therapeutics, Inc.

SEEL

1.03 USD

Dyadic International, Inc. logo

Dyadic International, Inc.

DYAI

1.06 USD

Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc.

ACHV

4.71 USD

Lantern Pharma Inc. logo

Lantern Pharma Inc.

LTRN

3.31 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

1.18 USD

BioVie Inc. logo

BioVie Inc.

BIVI

2.77 USD

CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc.

CASI

6.01 USD

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)